Professional Information

The links here point to professionally prepared sites and provide "official" information on Amyloidosis and treatment options such as principal published papers, abstracts and meeting notices with agendas/topics on relevant subjects.

At this time, it appears the Amyloidosis website for the Cornell Medical Center has the most information on the condition. The following medical journals that may also be helpful:

1) Amyloidosis

Morie A. Gertz* MD, Martha Q. Lacy MD, Angela Dispenzieri MD, Suzanne R. Hayman MD Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA Best Practice & Research Clinical Haematology Vol. 18, No. 4, pp. 709–727, 2005 This paper reviews a diagnostic pathway clinicians can use to diagnose the disorder, assess a patient’s prognosis, and logically plan a therapeutic strategy.

Download (Amyloidosis Gertz 2005.pdf) 242K>

2) Amyloidosis and Waldenström’s Macroglobulinemia

Morie A. Gertz, Giampaolo Merlini, and Steven P. Treon – ASH 2004 In Section I, Dr. Morie Gertz answers four specific questions: (1) When should amyloidosis be suspected? (2) How does one heighten ones index of suspicion for amyloid? (3) How is thediagnosis confirmed and the type classified as primary? (4) What is the prognosis and how is it accurately assessed?  In Section II, Dr. Giampaolo Merlini comprehensivelyreviews therapy of amyloidosis.  In Section III, Drs. Steven Treon and Giampaolo Merlini review the most current information on WM.

Download (WM and AL Merlini Gertz Treon 2004.pdf) 201K>

3) Autologous PBSCT in patients with cardiac amyloidosis Bone Marrow Transplantation

By Raymond L. Comenzo

Download (bmtlet.pdf) 30K>

4) Autologous SCT for Systemic Amyloidosis

By Raymond L. Comenzo and Morie A. Gertz

Download (BLOOD_6-15-2002_v99no12.pdf) 67K>

5) Bortezomib (VELCADE) in the treatment of AL amyloidosis: targeted therapy? (2007) Roberto Sitia, Giovanni Palladini, Giampaolo Merlini

Department of Biology and Technology, DiBiT, Università Vita-Salute, San Raffaele Scientific Institute Milan, Italy (RS); Amyloid Center, Biotechnology Research Laboratories, Fondazione IRCCS Policlinico San Matteo, Department of Biochemistry, University of Pavia, Italy (GP, GM). E-mail: gmerlini@unipv.it. DOI: 10.3324/haematol.12136

Download (2007 bortezomib AL - merlini.pdf) 258K>

6) CTD CHEMOTHERAPY IN SYSTEMIC AL AMYLOIDOSIS

Ashutosh D. Wechalekar, Hugh J.B. Goodman, Helen J. Lachmann, Mark Offer, Philip N. Hawkins, and Julian D. Gillmore From the National Amyloidosis Centre, Centre for Amyloidosis & Acute Phase Proteins, Department of Medicine (Hampstead Campus), Royal Free and University College Medical School,

London, United Kingdom.

Download (Safety and Efficacy of CTD in AL Amy 2006 NAC Blood1.pdf) 267K>

7) Definition of Organ Involvement and Treatment Response in Immunoglobulin Light Chain Amyloidosis (AL): A Consensus Opinion From the 10th International Symposium on Amyloid and Amyloidosis

Morie A. Gertz,* Ray Comenzo, Rodney H. Falk, Jean Paul Fermand, Bouke P. Hazenberg, Philip N. Hawkins, Giampaolo Merlini, Philippe Moreau, Pierre Ronco, Vaishali Sanchorawala, Orhan Sezer, Alan Solomon, and Giles Grateau - Am. J. Hematol. 79:319–328, 2005. This paper presents criteria that centers can now use to define organ involvement and uniform response criteria for reporting outcomes in patients with light chain AL.

Download (Definition of Organ involvement AJH July 2005.pdf) 119K>

8) Diagnosis and Management of the Cardiac Amyloidoses

Rodney H. Falk, MD - Department of Cardiology, Harvard Vanguard Medical Associates, Boston, MA USA

Circulation. 2005;112:2047-2060.

The purpose of this review is to familiarize the reader with the clinical features of amyloidosis and to address the approach to the patient with this disease, focusing on the various types of amyloidosis, their prognosis and treatment.

Download (CIRCULATION REVIEW CARDIAC AMYLOIDOSIS.pdf) 774K>

9) Efficacy of bortezomib (VELCADE) in systemic AL amyloidosis with relapsed/refractory clonal disease (2007) Ashutosh D. Wechalekar, Helen J. Lachmann, Mark Offer, Philip N. Hawkins,and Julian D. Gillmore

National Amyloidosis Centre, Centre for Amyloidosis & Acute Phase Proteins, Department of Medicine (Hampstead Campus), Royal Free and University College Medical School, London, United Kingdom

Download (2007 bortezomib UK.pdf) 242K>

10) GUIDELINES ON THE DIAGNOSIS AND MANAGEMENT OF AL AMYLOIDOSIS

By the British Committee for Standards in Hematology 2004 in conjunction with Working Group of the UK Myeloma Forum (UKMF).
Updates may be found at http://www.ukmf.org.uk and http://www.bcshguidelines.com

Download (BJH_guidlines_for_Amyloidosis.pdf) 195K>

11) High-Dose Melphalan and Autologous Stem-Cell Transplantation in Patients with AL Amyloidosis: An 8-Year Study

By Boston University Medical Center published in the 20 January 2004 issue of Annals of Internal Medicine (volume 140, pages 85-93)

Download (High-Dose_Melphalan.pdf) 360K>

12) Lenalidomide (REVLIMID) and dexamethasone in the treatment ofAL amyloidosis: results of a phase 2 trial (2007)

Vaishali Sanchorawala,1,2 Daniel G. Wright,1,2 Michael Rosenzweig,1,2 Kathleen T. Finn,1 Salli Fennessey,1 Jerome B. Zeldis,3 Martha Skinner,2 and David C. Seldin1,2; 2Amyloid Treatment and Research Program, BUMC, MA; 3Celgene, Summit, NJ

Download (2007 lenalidomide sanchorawala.pdf) 203K>

13) Measurement of Serum Free Light Chains in AL Amyloidosis

By the British Journal of Haematology, 2003, 122, 78-84; By The National Amyloidosis Centre and Centre for Amyloidosis and Acute Phase Proteins, Department of Medicine, Royal Free and University College Medical School, Royal Free Campus, London, UK.

Download (Measurement_of_Serum_Free_Light_Chains.pdf) 217K>

14) Melphalan and Dexamethasone in AL Amyloidosis

By Prof. Giampaolo Merlini, Amyloid Center - Biotechnology Research Laboratories; December 18, 2003; DOI10.1182/Blood-2003-08-2788. The association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis ineligible for stem cell transplantation.

Download (MELPHALAN_AND_HIGH-DOSE_DEX.pdf) 355K>

15) Myeloablative chemotherapy and stem cell transplantation in myeloma or primary amyloidosis with renal involvement

MORIE A. GERTZ, NELSON LEUNG, MARTHA Q. LACY, and ANGELA DISPENZIERI  Division of Hematology, Mayo Clinic, Rochester, Minnesota; and the Division of Nephrology, Mayo Clinic, Rochester, Minnesota

Stem cell transplantation presents unique challenges in patients with the nephrotic syndrome due to renal amyloid.

Download (ReviewResults_SCT_in_Renal_MM_AL_Amy_2005_Mayo.pdf) 94K>

16) Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study.

By Angela Dispenzieri and the Division of Hematology and Internal Medicine and the Division of Biostatistics, Mayo Clinic, Rochester, MN. Blood First Edition Paper on January 22, 2004; DOI 10.1182/blood-2003-12-4192.

Download (mayo_stem_cell_transplantation.pdf) 46K>

17) The activity of lenalidomide (REVLIMID) with or without dexamethasone in patients with primary systemic amyloidosis (2007)

Lenalidomide (initially known as CC-5013 and marketed as Revlimid® by Celgene) is a derivative of thalidomide.

Angela Dispenzieri,1,3 Martha Q. Lacy,1 Steven R. Zeldenrust,1 Suzanne R. Hayman,1 Shaji K. Kumar,1 Susan M. Geyer,2
John A. Lust,1,3 Jacob B. Allred,2 Thomas E. Witzig,1,3 S. Vincent Rajkumar,1 Philip R. Greipp,1,3 Stephen J. Russell,1,4
Brian Kabat,2 and Morie A. Gertz1
1Division of Hematology, 2Department of Biostatistics, 3Department of Laboratory Medicine, and 4Department of Molecular Medicine,
Mayo Clinic, Rochester, MN

Download (2007 lenalidomide dispenzieri.pdf) 360K>

18) The Laboratory Diagnosis and Monitoring of Amyloidosis

By Mayo Clinic, September 2002

Download (Laboratory_Diagnosis_and_Monitoring_of_Amyloidosis.pdf) 830K>

19) THE PHYSICIAN’S GUIDE TO AMYLOIDOSIS

Written By Dr. Rodney Falk, produced by NORD (The National Organization for Rare Disorders) and funded by the Amyloidosis Support Network, Inc. 2006 edition.

Download (Amyloidosis_booklet_4_3_06.pdf) 453K>

20) Treatment of light chain (AL) amyloidosis with the combination of bortezomib (VELCADE) and dexamethasone (2007)

Efstathios Kastritis, Athanasios Anagnostopoulos, Maria Roussou, Savvas Toumanidis, Constantinos Pamboukas, Magdalini Migkou, Anna Tassidou, Irini Xilouri, Sossana Delibasi, Erasmia Psimenou, Sofia Mellou, Evangelos Terpos, John Nanas, Meletios A. Dimopoulos...

Athens, Greece

Download (2007 velcade.pdf) 205K>

21) Understanding Thalidomide Therapy

©2001, International Myeloma Foundation North Hollywood, California

Download (thalidomide.pdf) 355K>

 

1) A Peptide-Based Vaccine Elicits CTL Responses Towards AL Amyloid-Related Immunoglobulin Light Chain

A proposed technique for use in clinical trials to eliminate the bone marrow plasma cells which produce amyloidogenic light chains.

Download (ASH 2006 Poster #241605.pdf) 19K

2) Amyloid in the cardiovascular system: A review

I Kholova´, H W M Niessen - Department of Pathology, Vrije Universiteit Medical Centre, Amsterdam, The Netherlands.  Published in J Clin Pathol 2005;58:125–133. doi: 10.1136/jcp.2004.017293

The cardiovascular system is a common target of amyloidosis. This review presents the current clinical and diagnostic approach to amyloidosis, with the emphasis on cardiovascular involvement

Download (Amyloid in the cardiovascular system.pdf) 289K

3) High-dose therapy for amyloidosis: the end of the beginning?

Blood, 15 May 2004, Vol. 103, No. 10, pp. 3612-3613 by Dr. Jayesh Mehta of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.

Download (High-dose_therapy_for_amyloidosis.pdf) 36K

4) Les amyloses à transthyrétine - Transthyretin Amyloidoses

La Revue de Médecine Interne, Volume 28, Issue 5, May 2007, Pages 306-313; N. Magy-Bertrand nmagy@chu-besancon.fr

Download (Abstract.pdf) 22K

5) Long-term follow-up of IgM monoclonal gammopathy of undetermined significance.

Blood. 2003 Nov 15;102(10):3759-64. Epub 2003 Jul 24 Kyle RA, Therneau TM, Rajkumar SV, Remstein ED, Offord JR, Larson DR, Plevak MF, Melton LJ 3rd. Division of Hematology and Internal Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA.

Download (follow_up_monoclonal_gammopathy.pdf) 41K

6) Primary Systemic Amyloidosis

Raymond L. Comenzo, MD 
Current Treatment Options in Oncology 2000, 1:83-89
Current Science, Inc. ISSN 1527-2729
Copyright © 2006 by Current Science, Inc.

Download (Primary Systemic Amyloidosis.pdf) 118K

7) Safety and efficacy of risk adapted cyclophosphamide, thalidomide and dexamethasone in systemic AL amyloidosis.

Hawkins PN, Wechalekar AD, Goodman HJB, Lachmann HJ, Offer M and Gillmore JD

National Amyloidosis Centre, UCL, London, UK

 

Download (ASH2006 Hawkins Poster.doc) 21K

8) Treatment of AL Amyloidosis with Tandem Cycles of High Dose Melphalan and Autologous Stem Cell Transplantation: Final Analysis of a Prospective Trial

Sanchorawala V, Wright DG, Quillen K, Finn KT, Dember LM, Berk J, Skinner M, Seldin DC. Boston University Medical Center, Boston, MA 02118, USA

Download (ASH2006 Sanchorawala.doc) 22K